Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
TCT 23: WATCH-TAVR: WATCHMAN for Patients with AF Undergoing TAVR
Author(s): Samir R Kapadia Added: 5 months ago
TCT 23 - We are joined by Dr Samir Kapadia (Cleveland Clinic, Cleveland, OH) to discuss the findings of the WATCH-TAVR Trial (NCT03173534). WATCH-TAVR aimed to evaluate the safety and effectiveness of left atrial appendage occlusion with the WATCHMAN device to prevent stroke and bleeding in patients with atrial fibrillation (AF) who are undergoing transcatheter aortic valve replacement (TAVR)… View more

Electrophysiology & Arrhythmia

Intervention
Repeat TAVR Outcomes: Promising Results for Selected Patients with Failed TAVR
Author(s): Raj Makkar Added: 6 months ago
In this insightful interview, investigator, Prof Raj R Makkar(Cedars-Sinai Heart Institute, US) joins us to discuss the outcomes of repeat transcatheter aortic valve replacement with balloon-expandable valves. Prof Makkar and his team used the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry to address a series of questions regarding the safety… View more

Intervention
ACC 2019: Corevalve low-risk TAVR Trial
Author(s): Nicolas M Van Mieghem , Michael J Reardon Added: 5 years ago
Prof Michael J Reardon (Houston Methodist, Texas, US) and Dr Nicolas van Mieghem (Rotterdam, NL) discuss the corevalve low-risk TAVR trial - self-expanding transcatheter or surgical aortic valve replacement in patients at low risk of surgical mortality. Filmed on site at ACC 2019 by Radcliffe Cardiology. Videography: Josh Birch Educational lead: Liam O'Neill (Chief Operating Officer) View more

Vascular Disease and Surgery
ACC 22: ADAPT-TAVR Shows SLT Does Not Affect CO for Patients After TAVR
Author(s): Duk-Woo Park Added: 2 years ago
In this short interview, Dr Duk-Woo Park (Asan Medical Center, KR) discusses the findings from the ADAPT-TAVR Randomized Clinical Trial (NCT03284827). The trial investigated Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR. Presented first at ACC.22, ADAPT-TAVR shows that the overall incidence of leaflet thrombosis on CT scans was less… View more

Anticoagulation
Controversies Regarding Subclinical Leaflet Thrombosis After TAVR
Author(s): Jolanta Siller-Matula , Mamas A Mamas , Kimberly Atianzar , et al Added: 3 years ago
A substantial number of patients develop a subclinical leaflet thrombosis (SLT) after transcatheter aortic valve replacement (TAVR). The thrombus forms on the leaflets, which can lead to valve dysfunction and possibly to early valve degeneration. Multidetector computed tomography is the most sensitive imaging technique at detecting SLT. Patients on antiplatelet drugs are at higher risk to… View more

Imaging & Diagnostics

Intervention
EuroPCR 21: TAVR for BAV Stenosis in Low Surgical Risk Patients
Author(s): Raj Makkar Added: 2 years ago
In this interview, Dr Raj Makkar (Cedars-Sinai Medical Center, Los Angeles, CA, US) discusses the Transcatheter Aortic Valve Replacement for bicuspid aortic stenosis in a patient population with low risk for surgery. Questions: What is the rationale for this study? Describe the design, patient population and endpoints? What are the key findings and what conclusions can be made? Which patients… View more

Intervention
Author(s): Nicolas M Van Mieghem Added: 6 years ago
In this video, Dr Nicolas Van Mieghem discusses which patients he is performing TAVR in now. View more

Intervention
ACC.24: The SMART Trial
Author(s): Howard C Herrmann Added: 1 week ago
ACC.24 — Investigator, Dr Howard C Hermann (Penn Medicine, Philadelphia, PA, US) joins us to discuss the findings from the SMART Trial (NCT04722250).This prospective, multi-center, randomized controlled study aims to investigate the valve safety and performance of self expanding as compared to balloon-expandable transcatheter aortic valve replacement (TAVR) in patients with small aortic annuli… View more

Intervention
Author(s): Nicolas M Van Mieghem Added: 6 years ago
In this video, Dr Nicolas Van Mieghem discusses the question; 'are we ready to be doing TAVR in low risk patients?'. View more

Intervention
PARTNER 3: TAVR is Cost Effective Compared with SAVR for Low-Risk Patients
Author(s): David J Cohen Added: 2 years ago
Dr David J Cohen (St Francis Hospital, Roslyn, NY, US) discusses the findings from PARTNER 3 Economic Study. The study, presented first at TCT 2021, showed that for patients with severe AS and low surgical risk, TF-TAVR with the SAPIEN 3 valve is cost-saving compared with SAVR at 2-year follow-up. Discussion Points Importance of the Study Used Data Complexities in Relation to the Costs of… View more

Intervention